Insilico Medicine and SK Biopharmaceuticals announced an AI-driven collaboration worth more than $2.5 billion to discover neuroimmune disorder drug candidates for central nervous system targets. The partnership, disclosed at BIO 2026 in San Diego, combines Insilico’s Pharma.AI platform with SK’s CNS development and commercialization capabilities. The deal structure includes an upfront component and near-term milestones, with additional payments tied to further development and regulatory progress. Insilico’s platform is positioned as a target-to-candidate engine, while SK Biopharmaceuticals would handle later-stage execution. The collaboration arrives amid heightened attention on how AI can compress early discovery timelines—particularly in indication areas with complex biology and long development cycles. For SK Biopharmaceuticals, the agreement expands beyond epilepsy into broader neuroimmune territories, while Insilico further enlarges its network of large pharma alliances across therapeutic areas.